Trimeris (Nasdaq: TRMS) has won a $4.9 million settlement with its partner Roche in a dispute over royalties for the AIDS drug Fuzeon.

The two companies have struck a new licensing agreement dating back to Jan. 1 under which the Durham firm will receive the payment, according to an SEC filing.

Read the SEC filing here.

Trimeris developed the drug Fuzeon. Roche is its manufacturing, marketing and distribution partner.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.